|
EP2006381B1
(en)
|
2006-03-31 |
2016-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for controlling blood pharmacokinetics of antibodies
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
CA3139492C
(en)
|
2007-09-26 |
2024-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
EP3056513A1
(en)
|
2008-04-11 |
2016-08-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
TWI761912B
(zh)
|
2010-11-30 |
2022-04-21 |
日商中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
EP2698431B1
(en)
*
|
2011-03-30 |
2020-09-09 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
|
EP4011913A1
(en)
|
2011-06-30 |
2022-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
AU2012317395B2
(en)
*
|
2011-09-30 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6093305B2
(ja)
*
|
2011-09-30 |
2017-03-08 |
中外製薬株式会社 |
抗原の消失を促進する抗原結合分子
|
|
EP2762493B1
(en)
*
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
EP2787081A4
(en)
*
|
2011-11-30 |
2015-10-07 |
Chugai Pharmaceutical Co Ltd |
PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
|
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
|
WO2013120929A1
(en)
|
2012-02-15 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
|
KR102219987B1
(ko)
*
|
2012-02-24 |
2021-02-25 |
추가이 세이야쿠 가부시키가이샤 |
ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
|
|
PT2825036T
(pt)
|
2012-03-16 |
2018-07-26 |
Regeneron Pharma |
Anticorpos de cadeia leve manipulados em histidina e roedores geneticamente modificados para gerar os mesmos
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
NZ629077A
(en)
|
2012-03-16 |
2015-12-24 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
CA2871807C
(en)
*
|
2012-04-27 |
2022-10-04 |
Bioatla, Llc |
Modified antibody regions and uses thereof
|
|
JPWO2013180201A1
(ja)
*
|
2012-05-30 |
2016-01-21 |
中外製薬株式会社 |
会合化した抗原を消失させる抗原結合分子
|
|
CN107759686A
(zh)
*
|
2012-05-30 |
2018-03-06 |
中外制药株式会社 |
靶组织特异性抗原结合分子
|
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
|
EP3721900A1
(en)
|
2012-08-24 |
2020-10-14 |
Chugai Seiyaku Kabushiki Kaisha |
Fcgammariib-specific fc region variant
|
|
WO2014104165A1
(ja)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
GB201302878D0
(en)
*
|
2013-02-19 |
2013-04-03 |
Argen X Bv |
Modified igG molecules
|
|
TWI636062B
(zh)
|
2013-04-02 |
2018-09-21 |
中外製藥股份有限公司 |
Fc region variant
|
|
CN105143262A
(zh)
|
2013-04-29 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
结合人fcrn的修饰的抗体和使用方法
|
|
ES2871383T3
(es)
|
2013-04-29 |
2021-10-28 |
Hoffmann La Roche |
Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso
|
|
DK3050896T3
(da)
|
2013-09-27 |
2021-07-19 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
|
|
MX2016003617A
(es)
|
2013-09-30 |
2016-07-21 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
|
|
US20160280787A1
(en)
|
2013-11-11 |
2016-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
|
EA201691154A1
(ru)
|
2013-12-04 |
2016-10-31 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающие молекулы, активность связывания антигена которых варьируется в зависимости от концентрации соединений, и библиотеки указанных молекул
|
|
WO2015107015A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with improved protein a-binding
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
CN106103478B
(zh)
|
2014-03-21 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
抗体体内半寿期的体外预测
|
|
EP3142700B1
(en)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
KR20170015920A
(ko)
*
|
2014-06-12 |
2017-02-10 |
에프. 호프만-라 로슈 아게 |
ＦｃＲｎ 상호작용이 변화된 항체를 선별하는 방법
|
|
FR3024453B1
(fr)
*
|
2014-08-01 |
2018-06-29 |
Lab Francais Du Fractionnement |
Procede de production de variants ayant un fc presentant une sialylation amelioree
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
MX2017005150A
(es)
*
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
|
WO2016073853A1
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
|
KR20170078677A
(ko)
|
2014-11-06 |
2017-07-07 |
에프. 호프만-라 로슈 아게 |
Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
|
|
WO2016076345A1
(ja)
|
2014-11-11 |
2016-05-19 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子のライブラリ
|
|
UA128712C2
(uk)
|
2014-12-19 |
2024-10-09 |
Чугаі Сейяку Кабусікі Кайся |
Антитіла проти c5 та способи застосування
|
|
JP6227191B1
(ja)
|
2014-12-19 |
2017-11-08 |
中外製薬株式会社 |
抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
|
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
|
US10464999B2
(en)
|
2015-01-28 |
2019-11-05 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
US10633433B2
(en)
|
2015-01-28 |
2020-04-28 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
US9879080B2
(en)
|
2015-01-28 |
2018-01-30 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
CN112142844B
(zh)
|
2015-02-05 |
2025-07-25 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
KR20180095740A
(ko)
|
2015-02-27 |
2018-08-27 |
추가이 세이야쿠 가부시키가이샤 |
Il-6 관련 질환 치료용 조성물
|
|
IL305148A
(en)
*
|
2015-09-15 |
2023-10-01 |
Scholar Rock Inc |
Anti-pro/hidden myostatin antibodies and their uses
|
|
UA120981C2
(uk)
|
2015-09-18 |
2020-03-10 |
Чугаі Сейяку Кабусікі Кайся |
Антитіло, що зв'язується з il-8, та його застосування
|
|
EP3390443A4
(en)
|
2015-12-18 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
|
|
MX2018008369A
(es)
|
2016-01-08 |
2019-05-15 |
Scholar Rock Inc |
Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
|
|
CA3024618A1
(en)
|
2016-05-27 |
2017-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
JP7275446B2
(ja)
*
|
2016-06-06 |
2023-05-18 |
シティ・オブ・ホープ |
Ｂａｆｆ－ｒ抗体及びその使用
|
|
MY191668A
(en)
|
2016-06-14 |
2022-07-06 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
CN109311969B
(zh)
|
2016-06-17 |
2022-09-27 |
中外制药株式会社 |
抗-肌肉生长抑制因子抗体及使用方法
|
|
EP3494134B1
(en)
|
2016-08-02 |
2025-12-10 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
|
SG11201900746RA
(en)
*
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
UA128669C2
(uk)
|
2016-10-14 |
2024-09-25 |
Ксенкор, Інк. |
ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
|
|
JP7198757B2
(ja)
|
2017-01-06 |
2023-01-04 |
スカラー ロック インコーポレイテッド |
ミオスタチン活性化の阻害により代謝疾患を処置するための方法
|
|
JP6974500B2
(ja)
*
|
2017-01-13 |
2021-12-01 |
ハンクス バイオファーマシューティクス，インコーポレイテッド |
ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|
|
KR20230043247A
(ko)
|
2017-01-31 |
2023-03-30 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
|
MA47449A
(fr)
*
|
2017-02-10 |
2019-12-18 |
Genmab Bv |
Variants polypeptidiques et ses utilisations
|
|
PL3583120T3
(pl)
|
2017-02-17 |
2023-01-09 |
Denali Therapeutics Inc. |
Konstruowane polipeptydy wiążące receptory transferyny
|
|
EP3608339B1
(en)
*
|
2017-04-07 |
2024-10-30 |
Kookmin University Industry Academy Cooperation Foundation |
Antibody fc variants for improving blood half-life
|
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
|
|
MX2019014576A
(es)
*
|
2017-06-05 |
2020-07-29 |
Janssen Biotech Inc |
Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
|
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
|
|
MX392444B
(es)
|
2017-07-27 |
2025-03-24 |
Alexion Pharma Inc |
Formulaciones de anticuerpos anti-c5 de alta concentracion.
|
|
WO2019033087A1
(en)
|
2017-08-11 |
2019-02-14 |
Research Development Foundation |
MODIFIED FC ANTIBODY VARIANTS FOR ENHANCED SERIAL HALF LIFE
|
|
BR112020006434A2
(pt)
|
2017-10-06 |
2020-11-03 |
Prothena Biosciences Limited |
anticorpos anti-transtirretina
|
|
KR102581734B1
(ko)
|
2017-10-06 |
2023-09-22 |
네오토프 뉴로사이언스 리미티드 |
트랜스타이레틴의 검출 방법
|
|
WO2019078357A1
(ja)
|
2017-10-20 |
2019-04-25 |
中外製薬株式会社 |
細胞への分子の取り込みを測定する方法
|
|
AU2018354404B2
(en)
|
2017-10-26 |
2025-10-30 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
|
|
MA50516A
(fr)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs procédés d'utilisation
|
|
US10538583B2
(en)
|
2017-10-31 |
2020-01-21 |
Staten Biotechnology B.V. |
Anti-APOC3 antibodies and compositions thereof
|
|
JP7731196B2
(ja)
|
2017-11-14 |
2025-08-29 |
中外製薬株式会社 |
抗Ｃ１ｓ抗体および使用方法
|
|
BR112020010483A2
(pt)
|
2017-11-29 |
2020-10-20 |
Prothena Biosciences Limited |
formulação liofilizada de um anticorpo monoclonal contra transtirretina
|
|
WO2019111871A1
(en)
|
2017-12-05 |
2019-06-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
|
|
MA51147A
(fr)
|
2017-12-13 |
2021-03-24 |
Regeneron Pharma |
Associations d'anticorps anti-c5 et utilisations associées
|
|
CA3089768A1
(en)
|
2018-02-02 |
2019-08-08 |
Oncoimmune, Inc. |
Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
|
|
KR20200142498A
(ko)
*
|
2018-02-02 |
2020-12-22 |
온코이뮨, 아이앤씨. |
암 치료를 위한 더 안전하고 더 효과적인 항-ctla-4 항체를 선택하고 설계하는 방법
|
|
JP7508368B2
(ja)
|
2018-03-15 |
2024-07-01 |
中外製薬株式会社 |
ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法
|
|
JP7328243B2
(ja)
*
|
2018-03-26 |
2023-08-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療薬を試験するためのヒト化げっ歯類
|
|
EP3773718A4
(en)
|
2018-04-06 |
2022-01-19 |
aTyr Pharma, Inc. |
COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES
|
|
JP7333789B2
(ja)
*
|
2018-04-13 |
2023-08-25 |
中外製薬株式会社 |
抗補体成分抗体および使用方法
|
|
WO2019204592A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
MX2020012091A
(es)
|
2018-05-14 |
2021-04-28 |
Oncoimmune Inc |
Composiciones anti-cd24 y usos de las mismas.
|
|
EP3802593B1
(en)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
EP3802603A1
(en)
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
|
|
GB201809341D0
(en)
*
|
2018-06-07 |
2018-07-25 |
Ucb Biopharma Sprl |
Multi-domain proteins with increased native state colloidal stability
|
|
AU2019295277B2
(en)
|
2018-06-26 |
2025-12-11 |
Kagoshima University |
Antibody binding to chondroitin sulfate proteoglycan-5
|
|
JP7397445B2
(ja)
|
2018-06-26 |
2023-12-13 |
協和キリン株式会社 |
Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
|
|
US12312394B2
(en)
|
2018-06-28 |
2025-05-27 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-C5 antibodies
|
|
DK4324851T3
(da)
|
2018-07-19 |
2025-10-06 |
Regeneron Pharma |
Kimæriske antigenreceptorer med BCMA-specificitet og anvendelser deraf
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
US20210301004A1
(en)
|
2018-08-01 |
2021-09-30 |
Chugai Seiyaku Kabushiki Kaisha |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
|
CR20210127A
(es)
|
2018-08-10 |
2021-04-19 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión al antigeno anti grupo de diferenciación 137 (cd137) y su uso
|
|
JP7662516B2
(ja)
|
2018-10-12 |
2025-04-15 |
ゼンコア インコーポレイテッド |
Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用
|
|
EA202191189A1
(ru)
|
2018-10-30 |
2021-08-06 |
Алексион Фармасьютикалс, Инк. |
Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг)
|
|
WO2020088164A1
(zh)
*
|
2018-11-01 |
2020-05-07 |
山东新时代药业有限公司 |
双特异性抗体及其用途
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック， インコーポレイテッド |
改変抗体ｆｃおよび使用方法
|
|
WO2020189748A1
(ja)
|
2019-03-19 |
2020-09-24 |
中外製薬株式会社 |
Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
|
|
CA3136398A1
(en)
|
2019-04-10 |
2020-10-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying fc region-modified antibody
|
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
|
EP3957325A4
(en)
*
|
2019-04-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
CHEMERA RECEPTOR RECOGNIZING AN ANTIBODY MODIFICATION SITE
|
|
CN114096562B
(zh)
|
2019-05-15 |
2025-02-21 |
中外制药株式会社 |
抗原结合分子、药物组合物和方法
|
|
US20220324969A1
(en)
*
|
2019-06-06 |
2022-10-13 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
WO2020247827A1
(en)
*
|
2019-06-06 |
2020-12-10 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
EP3980129A1
(en)
*
|
2019-06-07 |
2022-04-13 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
CA3146379A1
(en)
*
|
2019-07-08 |
2021-01-14 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
BR112022001693A2
(pt)
*
|
2019-07-30 |
2022-06-07 |
Mythic Therapeutics Inc |
Construtos de proteína de ligação ao antígeno e usos dos mesmos
|
|
AU2020330307A1
(en)
*
|
2019-08-12 |
2022-03-17 |
CSL Innovation Pty Ltd |
Complement C2 binding proteins and uses thereof
|
|
CA3156803A1
(en)
|
2019-10-03 |
2021-04-08 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|
|
US20220348679A1
(en)
*
|
2019-10-04 |
2022-11-03 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20220396618A1
(en)
*
|
2019-10-31 |
2022-12-15 |
The Research Foundation For The State University Of Newyork |
Rage antibodies, fragments and uses thereof
|
|
BR112022012010A2
(pt)
|
2019-12-18 |
2022-08-30 |
Hoffmann La Roche |
Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
|
|
MX2022007840A
(es)
|
2019-12-27 |
2022-07-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo.
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
CN115038721B
(zh)
*
|
2020-01-29 |
2025-04-01 |
高丽大学校产学协力团 |
pH敏感性Fc变体
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
WO2021204743A1
(en)
*
|
2020-04-08 |
2021-10-14 |
F. Hoffmann-La Roche Ag |
Large molecule unspecific clearance assay
|
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
|
EP4277931A1
(en)
|
2021-01-13 |
2023-11-22 |
Visterra, Inc. |
Humanized complement 5a receptor 1 antibodies and methods of use thereof
|
|
MX2023009146A
(es)
|
2021-02-03 |
2023-08-17 |
Mythic Therapeutics Inc |
Anticuerpos y usos de estos.
|
|
AU2022295067A1
(en)
|
2021-06-18 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
CA3220353A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
|
CN115572331A
(zh)
*
|
2021-07-06 |
2023-01-06 |
联邦生物科技(珠海横琴)有限公司 |
一种具有增强FcRn受体结合的突变子
|
|
WO2023023672A1
(en)
*
|
2021-08-20 |
2023-02-23 |
The Research Foundation For The State University Of New York |
IgA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION
|
|
WO2024092031A1
(en)
|
2022-10-25 |
2024-05-02 |
Seismic Therapeutic, Inc. |
VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
|
|
AU2023413166A1
(en)
|
2022-12-22 |
2025-07-03 |
Scholar Rock, Inc. |
Selective and potent inhibitory antibodies of myostatin activation
|
|
WO2024206214A1
(en)
*
|
2023-03-24 |
2024-10-03 |
Paragon Therapeutics, Inc. |
Fc fragments that bind fcrn and methods of use
|
|
AR133427A1
(es)
|
2023-07-31 |
2025-09-24 |
Sanofi Sa |
Anticuerpos anti-gprc5d y composiciones
|
|
GB202319605D0
(en)
|
2023-12-20 |
2024-01-31 |
argenx BV |
Monovalent binding molecules and methods of use
|
|
CN120365429B
(zh)
*
|
2025-06-30 |
2025-09-05 |
上海交通大学医学院附属仁济医院 |
Cd70特异性纳米抗体、分子影像探针及其制备方法和应用
|